Aclaris' Bosakitug Misses Phase 2 ADMIRATION Endpoint; Pivots to Oral Kinase and ATI-052 Programs
ACRS sits 46% above its 52-week low of $2.25 on light trading volume (0.4× avg).
Summary
Aclaris' anti-TSLP antibody bosakitug failed its Phase 2 ADMIRATION trial in atopic dermatitis on both primary and secondary endpoints, and shares fell 8.7% to $3.58. The company is steering investors toward modzatinib, ATI-9494 and ATI-052, with the first meaningful data (OLP cohort) not expected until the second half of 2027.
Updated with a Dow Jones Newswires report · What changed
Updates
· Dow Jones Newswires — Aclaris shares fell 8.7% to $3.58 after the bosakitug Phase 2 atopic dermatitis failure.
- Trial named Admiration; CEO Neal Walker said the anti-thymic stromal lymphopoietin monoclonal antibody alone did not overcome historical challenges of addressing atopic dermatitis.
Key Events · Product Development and Regulatory · ACRS
-
New · · Dow Jones Newswires
Shares Fall 8.7% on Bosakitug Failure
Aclaris shares fell 8.7% to $3.58 after the bosakitug Phase 2 atopic dermatitis failure.
-
Updated · · Dow Jones Newswires
Bosakitug Fails Phase 2 ADMIRATION Trial
The Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis did not achieve the primary endpoint of percent change in EASI score at Week 24, nor any secondary endpoints. Pharmacodynamic data showed TSLP target engagement and the drug was generally well tolerated, but efficacy failed. CEO Neal Walker said the anti-thymic stromal lymphopoietin monoclonal antibody alone did not overcome historical challenges of addressing atopic dermatitis.
-
Pipeline Reprioritized to Oral Kinase and ATI-052
Management said development priorities are unchanged: modzatinib (oral ITK/JAK3), ATI-9494 (ITK/TXK) and the anti-TSLP/IL-4Rα bispecific ATI-052. The Phase 2b ALPHA trial of modzatinib in lichen planus has been initiated with roughly 100 participants across OLP, CLP and LPP cohorts.
-
Next Data Readout Not Until 2H 2027
Top line results from the oral erosive lichen planus cohort of ALPHA are expected in the second half of 2027. ATI-9494 IND filing is expected in Q4 2026 with Phase 1 starting Q1 2027, and the ATI-052 Phase 2b trial in eosinophilic esophagitis is planned for Q1 2027.
-
Cash Position Funds the Pivot
Aclaris reported $204.6 million in cash and securities at Q3 2026 with runway into the first half of 2029, following $116.2 million net raised through its ATM during 2026 — enough to fund the remaining programs without an immediate raise.
Analysis · ACRS · Life Sciences
The lead anti-TSLP monoclonal antibody failed its Phase 2 atopic dermatitis trial outright — no primary or secondary endpoint hit — removing a program the market had been valuing, and the stock fell 8.7% to $3.58. CEO Neal Walker said the anti-thymic stromal lymphopoietin monoclonal antibody alone did not overcome historical challenges of addressing atopic dermatitis. Management is explicit that priorities do not change: the story now rests on the oral ITK/JAK3 inhibitor modzatinib (Phase 2b ALPHA just started, OLP data in 2H 2027), ATI-9494 (IND this quarter, Phase 1 in Q1 2027) and the anti-TSLP/IL-4Rα bispecific ATI-052 (EoE Phase 2b in Q1 2027). With $204.6M in cash per the Q3 report, the balance sheet buys time, but the next hard readout is more than a year out, so the stock's value now hinges on whether investors re-rate the remaining pipeline after losing the bosakitug leg.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRS was trading at $3.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $621.8M. The 52-week trading range was $2.25 to $6.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.